GSK Abandons Herpes Vaccine After Disappointing Phase I/II Proof-of-Concept Data
Without revealing specific details, GSK announced that it is terminating the development of its investigational herpes simplex virus vaccine after failing to meet the study’s primary efficacy objective.
GSK Ends Development of Herpes Vaccine Candidate After Disappointing Trial Results
A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.
GSK’s Herpes Shot Fails in Early Trial in Blow for Drugmaker
GSK Plc’s experimental vaccine for herpes failed in an early-stage trial, halting an effort to bring the first shot for the condition to market.
GSK's experimental herpes vaccine fails to meet main goal in trial
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main goal of a mid-stage trial and would not be taken forward to a late-stage trial.
GSK’s experimental herpes shot fails in early trial
GSK's HSV vaccine candidate fails mid-stage trial, will not progress to late-stage trial. No safety concerns observed.
GSK's HSV Vaccine Study Fails to Meet Primary Efficacy Goal
GSK plc GSK announced that its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet the primary endpoint in the combined phase I/II proof-of-concept study. The phase I/II TH HSV REC-003 study evaluated the clinical efficacy of the early-stage HSV vaccine candidate GSK3943104.
GSK’s Phase I/II herpes simplex vaccine trial misses primary endpoint
GSK has announced that Part II of the Phase I/II TH HSV REC-003 trial of its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet its primary efficacy endpoint. The results were evidenced in an analysis of primary objective data from the Phase II part of the trial.
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...
pharmaphorum7d
GSK drops HSV jab, leaving rival mRNA shots in pole position
GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ...
Rolling Out4d
4 reasons to prevent a fever blister from returning
While they can heal naturally, preventing a fever blister from recurring should be a priority for anyone who has experienced ...
GSK discontinues herpes vaccine; Roivant launches new ‘vant’ around hypertension drug
The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity ...
tyla9d
Body waxer issues important advice to anyone with specific STI before going into appointment
It's easy to assume that people with genital herpes will be turned away from receiving an intimate wax - but Jess reassures ...
Monthly Prescribing Reference8d
GSK Ends Development of Herpes Vaccine Candidate After Disappointing Trial Results
An analysis of data from the phase 2 portion of the trial showed the primary efficacy objective had not been met. A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine ...